FIGURE 3.

The use of CDK4/6 inhibitors since the reimbursement date in patients diagnosed with HR+/HER2− ABC between 2009 and August 2017, and alive on August 1, 2017. (A) Cumulative use of CDK4/6 inhibitors since reimbursement date by competing risk methodology. (B) First‐given new line of therapy since reimbursement date in patients that switched systemic therapy (n = 248). ABC, advanced breast cancer; CDK4/6, cyclin‐dependent kinase 4/6; CDK4/6i, CDK4/6 inhibitors; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; mTOR, mTOR inhibitors [Color figure can be viewed at wileyonlinelibrary.com]